20/20 BioLabs Posts Strong Growth as Nasdaq Listing, Funding Fuel Expansion
$AIDX reports 17% revenue growth to $2.0M in FY2025, 68% gross profit surge, and 33% net loss improvement following Nasdaq listing and $5M funding round.
IBMAIDXrevenue growthNasdaq listing